Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDRODERM vs MANNITOL 15%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.
FDA-approved: testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Off-label: delayed puberty in males, female-to-male transgender hormone therapy.
Reduction of intracranial pressure (FDA-approved),Reduction of intraocular pressure (FDA-approved),Promotion of diuresis in oliguric phases of acute renal failure (off-label),Cerebral edema (off-label)
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
Terminal elimination half-life approximately 0.25-1.5 hours in normal renal function; prolonged to 24-36 hours in renal impairment.
Testosterone is metabolized primarily in the liver via CYP3A4 and CYP2C9 isoenzymes, as well as by 5α-reductase to dihydrotestosterone (DHT) and by aromatase to estradiol.
Mannitol is not significantly metabolized; it is primarily excreted unchanged by the kidneys via glomerular filtration.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Primarily renal (90-100% as unchanged drug); negligible biliary/fecal elimination.
Approximately 98–99% bound: primarily to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%).
Approximately 0-10% bound to plasma proteins (negligible binding).
Volume of distribution is approximately 0.2–0.8 L/kg, reflecting distribution into steroid-sensitive tissues and binding proteins.
0.5-0.8 L/kg; primarily distributes in extracellular fluid (interstitial space).
Transdermal bioavailability is approximately 10–15% of the nominal dose (based on 24-hour application), with interindividual variability due to skin permeability.
Intravenous: 100% (only route used therapeutically); not administered orally due to minimal absorption (oral bioavailability < 5%).
No specific dose adjustment recommended for renal impairment. Use with caution in patients with severe renal impairment due to potential fluid retention.
Contraindicated in anuria due to severe renal disease. For GFR <50 m L/min, use with caution and monitor serum osmolarity and renal function. No specific dose reduction defined; consider alternative therapy if GFR <20 m L/min.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment guidelines.
No specific adjustment for Child-Pugh class. Use with caution in ascites or severe hepatic impairment due to risk of volume overload and electrolyte disturbances.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in children <18 years.
0.25-1 g/kg (1.67-6.67 m L/kg of 15% solution) intravenously over 30-60 minutes. Repeat doses as needed based on clinical response, up to 1-2 g/kg.
Initiate at 2.5 mg once daily in elderly patients due to increased risk of adverse effects, particularly prostatic hyperplasia and cardiovascular events. Monitor serum testosterone levels and adjust as needed.
Initiate with lower doses (e.g., 0.5 g/kg) and titrate carefully due to increased risk of volume overload, electrolyte imbalance, and renal impairment. Monitor renal function, serum osmolarity, and fluid status closely.
WARNING: Cardiovascular risk - Increased risk of myocardial infarction, stroke, and cardiovascular death has been reported with testosterone replacement therapy. Only use in men with confirmed hypogonadism.
None
Elderly patients and those with known cardiovascular risk factors should be monitored for cardiovascular events.,May exacerbate sleep apnea in predisposed individuals.,Can cause erythrocytosis; monitor hematocrit.,May accelerate growth of prostate cancer and benign prostatic hyperplasia; monitor prostate-specific antigen (PSA).,Monitor for signs of virilization in women if used off-label.,Possible hypercalcemia in immobilized patients.
May cause volume expansion, pulmonary congestion, or heart failure in patients with cardiac dysfunction. Monitor serum electrolytes, osmolality, and renal function. Use with caution in patients with renal impairment, as accumulation can cause metabolic acidosis. Risk of osmotic nephrosis or acute kidney injury with high doses or prolonged use. May exacerbate intracranial hemorrhage due to increased cerebral blood volume.
Men with carcinoma of the breast or known or suspected carcinoma of the prostate.,Women who are pregnant or may become pregnant (risk of virilization of fetus).,Hypersensitivity to testosterone or any component of the product.,Severe renal or hepatic impairment (risk of fluid retention).
Anuria due to severe renal disease, severe pulmonary congestion or edema, active intracranial bleeding (except during craniotomy), severe dehydration, and known hypersensitivity to mannitol.
No known food interactions. Take with or without food.
No significant food interactions. Avoid excessive sodium intake to prevent fluid retention.
Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, clitoromegaly) with androgen exposure during critical period of genital differentiation (weeks 8-12). Second and third trimesters: risk of clitoral enlargement, advanced bone age, and potential long-term behavioral effects. Male fetuses may experience premature sexual development. No adequate studies; USP pregnancy category X.
Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimesters: Use only if clearly needed, as osmotic diuresis may cause fetal dehydration, electrolyte imbalances, or altered placental blood flow. There is no evidence of direct teratogenicity.
Testosterone is excreted into human milk; M/P ratio not established. Potential for virilization of female infants and early puberty in male infants. Risk of suppression of maternal lactation (androgen-induced decrease in prolactin). Contraindicated during breastfeeding; alternative therapies recommended.
Mannitol is not known to be excreted into human milk. M/P ratio is not established due to lack of data. Due to its high molecular weight and poor oral bioavailability, infant exposure via breastfeeding is likely negligible. Use with caution in lactating women only if clearly needed.
Androderm is contraindicated in pregnancy; no dose adjustments applicable. If therapy is necessary for maternal hypogonadism, discontinue immediately upon pregnancy recognition. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication. Do not dose in pregnancy.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes in pregnancy (increased plasma volume and renal clearance) may require higher doses to achieve desired effect. Monitor clinical response and adjust dosing based on urine output and serum osmolality.
Apply to clean, dry, intact skin on the abdomen, thighs, upper arms, or back. Rotate application sites to minimize skin reactions. Do not apply to genitals or scrotum. Avoid showering or swimming for at least 3-4 hours after application to ensure absorption. Monitor serum testosterone levels 14 days after starting therapy or dose adjustment, drawn in the morning before application. Use with caution in patients with known or suspected prostate cancer or breast cancer. Warn patients about the risk of transfer to women and children through skin contact; cover application site with clothing or wash skin before contact.
Monitor serum osmolality and electrolyte levels closely during therapy; use in cerebral edema requires maintaining serum osmolality 310-320 m Osm/L. Administer via in-line filter (0.22 micron) to prevent crystal emboli. Rapid infusion may cause transient hypervolemia; caution in heart failure or renal impairment. Onset of diuresis is 1-3 hours after IV administration.
Apply the gel to clean, dry, intact skin once daily in the morning.,Rotate application sites to prevent skin irritation.,Avoid direct skin contact with women and children; wash hands thoroughly after application and cover the site with clothing.,Do not apply to the genitals or scrotum.,Do not shower or swim for at least 3-4 hours after application.,Monitor for signs of skin irritation, such as redness or itching.,Report any swelling of the ankles, difficulty breathing, or changes in mood or sleep.,Keep the medication away from children and pets.
This medication increases urine output to reduce fluid buildup.,Report any chest pain, difficulty breathing, or swelling in ankles/feet.,You may experience headache, nausea, or dry mouth.,Avoid excessive salt intake to prevent fluid retention.,Notify your doctor if you have kidney disease or heart conditions.
No interactions on record
"Concomitant use of clonidine and mannitol may potentiate the hypotensive effect of clonidine, leading to an increased risk of severe hypotension, syncope, and orthostatic hypotension. Mannitol, an osmotic diuretic, can cause volume depletion and electrolyte disturbances, which may exacerbate clonidine's sympatholytic effects on blood pressure regulation. This interaction is particularly concerning in patients with pre-existing cardiovascular conditions or those receiving other antihypertensive agents."
"Mannitol, an osmotic diuretic, induces intravascular volume expansion followed by diuresis, which can cause electrolyte disturbances, particularly hypokalemia and hypomagnesemia. Nifedipine, a calcium channel blocker, can further lower blood pressure through vasodilation. The combination may enhance the hypotensive effect and increase the risk of arrhythmias due to electrolyte imbalances."
"Coadministration of candesartan cilexetil, an angiotensin II receptor blocker (ARB), with mannitol, an osmotic diuretic, can result in an additive hypotensive effect due to overlapping mechanisms that reduce blood pressure. Mannitol increases renal water excretion, decreasing plasma volume and preload, while candesartan inhibits angiotensin II-mediated vasoconstriction and aldosterone secretion, leading to vasodilation and reduced afterload. This combined effect may predispose patients to symptomatic hypotension, especially in those with volume depletion or renal impairment."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDRODERM vs MANNITOL 15%, answered by our medical review team.
ANDRODERM is a Androgen that works by Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.. MANNITOL 15% is a Osmotic Diuretic that works by Increases plasma osmolality, drawing water from intracellular and interstitial spaces into the vascular compartment, thereby reducing intracranial pressure and intraocular pressure. Acts as an osmotic diuretic in the kidneys, increasing urine flow by inhibiting water reabsorption in the proximal tubule and loop of Henle.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDRODERM and MANNITOL 15% depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDRODERM is: Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.. The standard adult dose of MANNITOL 15% is: 1-2 g/kg as a 15% solution intravenously over 30-60 minutes. Typical adult dose: 100-200 g (667-1333 m L of 15% solution) administered as a single dose for reduction of intracranial pressure or promotion of diuresis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDRODERM and MANNITOL 15% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDRODERM is classified as Category C. Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, . MANNITOL 15% is classified as Category A/B. Mannitol is a category C drug. First trimester: No well-controlled studies, but animal studies have not shown teratogenic effects; risk cannot be excluded. Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.